Consumers increasingly prioritize natural health solutions that combine efficacy with convenient delivery formats. In response to this trend, Sirio developed three gummies with clinically researched macrobiotic strains, which the company will launch at next week’s CPHI 2024 trade show (October 8–10). 

The range includes GummiBiotics Defense to help support immune health, GummiBiotics IBS Ease to alleviate irritable bowel syndrome (IBS) symptoms and GummiBiotics Lean to aid in abdominal fat burning. 

Sara Lesina, general manager of Sirio Europe and Americas, says that “each one of these concepts is a true first for nutraceutical brands.”

“We are excited to launch the new GummiBiotics range as it continues building on our partnerships with some of the best ingredient suppliers, and it combines the benefits of science-backed biotics with gummies that are delicious: this range will change the experience for consumers.” 

Clinically researched ingredients

Sirio collaborated with its customers to create the new gummies. GummiBiotics Defense contains 500 mg of EpiCor postbiotic per serving, a baker’s yeast-derived postbiotic developed by Cargill. 

This ingredient is backed by over 15 published immune and gut health studies. The company notes this is a “first-to-market postbiotic” and the only available gummy featuring EpiCor.